Wednesday, June 08, 2016 1:22:26 AM
In May 2011, they elaborate on the 33 patients, making it clear that not all patients were in the blinded portion of the study.
There were likely probably a good 17 that were in the "open" pre-placebo days "information arm", which is not the same thing as a compassionate use arm. That was determined by Dr. Gruber's comments. Hope this helps.
Rough timeline:
-- NCT opened in 2006 continues to today
-- Open randomized study began in 2007 without placebo
-- Four clinical sites, screened roughly 50 patients; Recruitment in control arm poor due to patients knowing classification, control patients dropped out per 2007 10K (repeated 10K verbiage subsequent years: 2008, 2009, etc.)
-- recruitment stopped in 2007/2008 and company developed a placebo; obtained renewals of institutional review board or IRB approvals and other necessary steps; reinitiated approvals at all clinical sites, approvals granted.
-- Kathy Montag surgery in December 2007; joined DCVax Ph II Double-blinded study but didn't get vaccine until April/May 2008
-- Double-blinded study PR to start in May 2008
-- Dr. Gruber, Principal Investigator for NYU and Overlook quoted stating in the Star Ledger in June 2008 “Overlook is running the trial in conjunction with NYU and so far has enrolled 20 patients." - His quote had to have included both “open - pre-placebo patients” and “double-blinded patients”. See next bullet
-- June 2008 10Q, released on August 19, 2008, company quoted as "to date only 6 patients have enrolled in the clinical trial, which is designed to include 240-patients. Given our lack of funding, it is unclear how quickly we will be able to increase enrollment, if at all. unsure if they could enroll more, financial constraints."
-- Nurses blog in Sept 2008 story on Kathy Montag, Overlook Nurse, as that time Overlook reported to have enrolled 3 patients in Double Blinded Phase III since it began (a drop of 17 patient count from Dr. Gruber's June statement).
-- Sept 2008 10Q released on November 19, 2008, again company quoted "to date only 11 patients have enrolled in the clinical trial, which is designed to include 240-patients. Given our lack of funding, it is unclear how quickly we will be able to increase enrollment, if at all."
-- January 2009, 13 sites prepared and ready to enroll (only 4 were recruiting though; and they were laying off employees, down from 7 to 4 so doubtful that they enrolled a single patient during this time; they did try to raise money and kept it open for a while)
-- NCT site records recruiting as stopped mid-year.
-- January 2011 PR [mine]:
To date, this trial has been conducted at 13 clinical sites across the U.S., with 33 patients already having been enrolled.
These patients have continued to be treated with the DCVax® regimen and follow-up during the last two years. The only aspect of the trial that stopped for a period of time was the enrollment of additional new patients beyond the 33 patients who were already enrolled and receiving ongoing treatment.
[only 4 were recruiting per 2009 10k statements; when they speak of trial, they mean NCT # 2006-forward];
— May 2011 PR, they elaborate more on the 33 patients (from both the 2007-2008 (open label) and 2008-2009 (double-blinded) period), and it is clear they are mix of “double blinded main arm” and “information arm”, which is not the same thing as CUA:
“To date 33 patients have already been enrolled in this ongoing 240-patient GBM brain cancer trial and its information arm, and have been proceeding through the treatment regimen and follow-up”.
[240-patient GBM brain cancer trial, meaning the entire NCT #, as it changed from 141-patients to 240-patients, as they don’t just state double-blinded.]
— When the study resumed in August 2011, the compassionate use arm existed (CUA).
— Revamped as Phase III, in 2012, they stopped the CUA, added a psPD arm and all "failed screen" patients had to pass baseline 2 to enter psPD arm.
Recent NWBO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 08:30:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 02:42:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/30/2024 11:49:38 PM
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
Maybacks Global Entertainment and ZEASN Technology Private Ltd. Sign Global Licensing Agreement • AHRO • Aug 8, 2024 7:00 AM
SANUWAVE Will Host a Conference Call on August 13, 2024 at 8:30 AM (ET) to Present Q2 Financial Results • SNWV • Aug 8, 2024 6:59 AM
Kona Gold Beverage Inc. Signs Letter of Intent with Bemax, Inc. to Sell Kona Gold, LLC • BMXC • Aug 7, 2024 10:00 AM
Btab Ecommerce Group, Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • BBTT • Aug 7, 2024 9:00 AM
Hydromer, Inc. Announces Preliminary Unaudited Second Quarter 2024 Financial Results and Provides Business Update • HYDI • Aug 7, 2024 8:52 AM
North Bay Resources Announces Mt. Vernon Gold Mine Startup, Sierra County, California • NBRI • Aug 5, 2024 9:00 AM